-+ 0.00%
-+ 0.00%
-+ 0.00%

Galmed partners with Barcode Nanotech on heart-targeted Aramchol LNP formulation

PUBT·07/16/2026 11:31:24
Listen to the news
Galmed partners with Barcode Nanotech on heart-targeted Aramchol LNP formulation
  • Galmed entered a collaboration with Barcode Nanotech to develop a cardiac-targeted lipid nanoparticle formulation of its SCD1 inhibitor Aramchol.
  • Program aims to redirect Aramchol biodistribution from liver hepatocytes to heart muscle, positioning it for cardiac fibrosis and other heart diseases.
  • Work uses in vivo screening of hundreds of nanoparticle candidates with AI-enabled analysis to identify formulations with improved cardiac targeting.
  • Collaboration also targets modified LNPs to selectively engage cardiac cell types, supporting Aramchol-based programs and future candidates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160730PR_NEWS_USPR_____LN06139) on July 16, 2026, and is solely responsible for the information contained therein.